CD274 and urothelial carcinoma: A Phase 2 trial on PD-L1-positive urothelial carcinoma patients during or after platinum-containing chemotherapy (n=113, median follow-up 9.4 months) has a 24% confirmed objective response rate (10 complete responses and 15 partial responses), 68% sustained response among responders, and median progression-free survival and overall survival were 2.1 and 9.8 months respectively (7).